Literature DB >> 17340165

Bisphosphonates.

Ian R Reid1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17340165     DOI： 10.1007/s00256-006-0266-2

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN： 0364-2348            Impact factor:   2.199


× No keyword cloud information.
  10 in total

1.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Authors:  D M Black; D E Thompson; D C Bauer; K Ensrud; T Musliner; M C Hochberg; M C Nevitt; S Suryawanshi; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.

Authors:  Ian R Reid; James S Davidson; Diana Wattie; Fiona Wu; Jenny Lucas; Gregory D Gamble; Michael D Rutland; Tim Cundy
Journal:  Bone       Date:  2004-07       Impact factor: 4.398

3.  Osteonecrosis of the jaw--do bisphosphonates pose a risk?

Authors:  John P Bilezikian
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

4.  Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Authors:  Ian R Reid; Paul Miller; Kenneth Lyles; William Fraser; Jacques P Brown; Youssef Saidi; Peter Mesenbrink; Guoqin Su; Judy Pak; Ken Zelenakas; Monica Luchi; Peter Richardson; David Hosking
Journal:  N Engl J Med       Date:  2005-09-01       Impact factor: 91.245

Review 5.  Management of bone metastases in cancer: a review.

Authors:  Giovanni Selvaggi; Giorgio V Scagliotti
Journal:  Crit Rev Oncol Hematol       Date:  2005-06-23       Impact factor: 6.312

6.  Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.

Authors:  B J Riis; J Ise; T von Stein; Y Bagger; C Christiansen
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

7.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Authors:  M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

Review 8.  Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

Authors:  Ann Cranney; George Wells; Andrew Willan; Lauren Griffith; Nicole Zytaruk; Vivian Robinson; Dennis Black; Jonathan Adachi; Beverley Shea; Peter Tugwell; Gordon Guyatt
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

Review 9.  Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.

Authors:  Ann Cranney; Peter Tugwell; Jonathan Adachi; Bruce Weaver; Nicole Zytaruk; Alexandra Papaioannou; Vivian Robinson; Beverley Shea; George Wells; Gordon Guyatt
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

10.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245
  10 in total
  5 in total

Review 1.  Founders lecture 2007: Metabolic bone disease: what has changed in 30 years?

Authors:  Murali Sundaram
Journal:  Skeletal Radiol       Date:  2009-03-05       Impact factor: 2.199

2.  Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.

Authors:  Alessandro Corsi; Ernesto Ippolito; Pamela G Robey; Mara Riminucci; Alan Boyde
Journal:  Skeletal Radiol       Date:  2017-06-28       Impact factor: 2.199

3.  Temporal progression of skeletal cystic angiomatosis.

Authors:  Giridhar M Shivaram; Reetesh K Pai; Kevin B Ireland; Kathryn J Stevens
Journal:  Skeletal Radiol       Date:  2007-10-03       Impact factor: 2.199

4.  RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects.

Authors:  C Di Nisio; V L Zizzari; S Zara; M Falconi; G Teti; G Tetè; A Nori; V Zavaglia; A Cataldi
Journal:  Eur J Histochem       Date:  2015-02-03       Impact factor: 3.188

5.  Long-term treatment with alendronate increases the surgical difficulty during simple exodontias - an in vivo observation in Holtzman rats.

Authors:  Nicolau Conte-Neto; Alliny de Souza Bastos; Luis Carlos Spolidorio; Rosemary Adriana Chierici Marcantonio; Elcio Marcantonio
Journal:  Head Face Med       Date:  2012-07-26       Impact factor: 2.151
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.